PharmaEssentia
PharmaEssentia
Explore linked clinical trials.11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 | 2026-10-01 | NCT07521046 | |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations | Alfa-2b; Azacitidine; MDS/AML; Ropeginterferon | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-25 | NCT07646821 | |
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, myeloproliferative neoplasm, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-08-13 | NCT06468033 | |
| Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Not applicable | 2026-07-29 | NCT07734272 | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04285086 | |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blood platelet disease, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, thrombocytosis disease | Not yet recruiting | Phase 2 | 2026-05-06 | NCT07468916 | |
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-04-01 | NCT07047885 | |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, neoplasm, thrombocytosis disease | Active, not recruiting | Phase 2 | 2025-08-13 | NCT05482971 | |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, polycythemia, thrombocytosis disease | Active, not recruiting | Phase 3 | 2025-08-13 | NCT05481151 | |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2025-08-03 | NCT05485948 | |
| Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | Advanced Solid Tumors | Enrolling by invitation | Phase 1 | 2025-07-08 | NCT07053904 |